Cantor Fitzgerald Cuts Earnings Estimates for Cytokinetics

Cytokinetics, Incorporated (NASDAQ:CYTK) – Research analysts at Cantor Fitzgerald cut their FY2026 earnings per share (EPS) estimates for shares of Cytokinetics in a research report issued on Thursday, November 6th. Cantor Fitzgerald analyst C. Gould now forecasts that the biopharmaceutical company will post earnings of ($6.56) per share for the year, down from their previous forecast of ($6.39). Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Cytokinetics’ current full-year earnings is ($5.24) per share.

Other equities research analysts have also recently issued reports about the stock. Citigroup boosted their price objective on shares of Cytokinetics from $77.00 to $84.00 and gave the company a “buy” rating in a research report on Tuesday, September 2nd. Barclays boosted their price target on Cytokinetics from $71.00 to $82.00 and gave the company an “overweight” rating in a report on Monday, October 6th. Needham & Company LLC reiterated a “buy” rating and set a $72.00 price objective on shares of Cytokinetics in a report on Tuesday, September 2nd. Bank of America lifted their target price on Cytokinetics from $52.00 to $56.00 and gave the company a “neutral” rating in a research report on Thursday, October 2nd. Finally, B. Riley upped their price target on Cytokinetics from $74.00 to $80.00 and gave the stock a “buy” rating in a research report on Monday, September 22nd. Thirteen investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $76.64.

Cytokinetics Stock Down 0.2%

Cytokinetics stock opened at $60.16 on Monday. The company has a 50 day moving average of $55.26 and a 200-day moving average of $42.13. Cytokinetics has a twelve month low of $29.31 and a twelve month high of $64.13. The stock has a market capitalization of $7.36 billion, a PE ratio of -11.80 and a beta of 0.58.

Cytokinetics (NASDAQ:CYTK) last posted its earnings results on Wednesday, November 5th. The biopharmaceutical company reported ($1.54) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.59) by $0.05. The business had revenue of $1.94 million for the quarter, compared to the consensus estimate of $6.05 million. Cytokinetics’s revenue for the quarter was up 318.1% compared to the same quarter last year. During the same period in the previous year, the company posted ($1.36) earnings per share.

Institutional Trading of Cytokinetics

Several institutional investors and hedge funds have recently added to or reduced their stakes in CYTK. Skandinaviska Enskilda Banken AB publ grew its position in shares of Cytokinetics by 280.7% in the 3rd quarter. Skandinaviska Enskilda Banken AB publ now owns 149,957 shares of the biopharmaceutical company’s stock valued at $8,242,000 after acquiring an additional 110,568 shares during the period. Fifth Third Bancorp raised its holdings in shares of Cytokinetics by 32.3% in the 3rd quarter. Fifth Third Bancorp now owns 1,072 shares of the biopharmaceutical company’s stock valued at $59,000 after purchasing an additional 262 shares during the period. PNC Financial Services Group Inc. lifted its stake in Cytokinetics by 28.5% in the 3rd quarter. PNC Financial Services Group Inc. now owns 6,049 shares of the biopharmaceutical company’s stock valued at $332,000 after purchasing an additional 1,343 shares during the last quarter. Aberdeen Group plc grew its holdings in Cytokinetics by 0.5% during the third quarter. Aberdeen Group plc now owns 927,832 shares of the biopharmaceutical company’s stock worth $50,994,000 after purchasing an additional 4,903 shares during the period. Finally, Assetmark Inc. grew its holdings in Cytokinetics by 27.3% during the third quarter. Assetmark Inc. now owns 3,363 shares of the biopharmaceutical company’s stock worth $185,000 after purchasing an additional 721 shares during the period.

Insider Buying and Selling

In other Cytokinetics news, Director Wendell Wierenga sold 4,375 shares of the firm’s stock in a transaction that occurred on Monday, October 27th. The stock was sold at an average price of $58.68, for a total value of $256,725.00. Following the completion of the transaction, the director directly owned 32,444 shares in the company, valued at $1,903,813.92. This trade represents a 11.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Edward M. Md Kaye sold 6,757 shares of the business’s stock in a transaction that occurred on Monday, October 6th. The stock was sold at an average price of $60.00, for a total value of $405,420.00. Following the transaction, the director directly owned 9,778 shares in the company, valued at $586,680. This trade represents a 40.86% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 56,983 shares of company stock valued at $3,165,356. 2.70% of the stock is currently owned by company insiders.

Cytokinetics Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.